Navigation Links
Femtogram Sensitivity of the Antipsychotic Drugs Raclopride and Ritanserin Using a Varian 1200L LC/MS/MS

J. Beck and C. Schmidt
Varian, Inc.

Introduction

Ritanserin (Tisterton) is a serotonin-2 antagonist drug shown to be effective in the treatment of anxiety and depression1 while Raclopride acts as a dopamine D2 receptor antagonist.2 These two compounds were used to demonstrate low-level sensitivity of the Varian 1200L LC/MS/MS in selected reaction monitoring mode (SRM). Studies have shown LC/MS to be a useful tool in the quantitation of low levels of Raclopride.3

Instrumentation

Varian 1200L LC/MS/MS equipped with ESI source

Materials and Reagents

Ritanserin ordered from Sigma-Aldrich Corp.,Catalog Number R-103

S-(-)-Raclopride ordered from Sigma-Aldrich Corp.,Catalog Number R-121

All other chemicals are reagent grade or HPLC grade

Sample Preparation

Milligram quantities were prepared and dissolved in a 50:50 mixture of acetonitrile/water with 0.1% formic acid. Serial dilutions were made from each stock solution prior to flow injection analysis (FIA). Samples were injected into a mobile phase of 50:50 acetonitrile/0.1% formic acid which was pumped directly into the mass spectrometer at 0.2 mL/min. A 5 μL loop was used for the injections and the injections were repeated five times for each concentration level.

Results and Discussion

Raclopride Five replicates at five different concentration levels were run. FIA injections of Raclopride at its lowest detectable limit, 100 pg/mL (500 fg on-column), is shown in Figure 1. At the lowest level, the S/N ratio is approximately 10:1 for the raw data. Also, a plot at a higher concentration of 10 ng/mL is included for comparison (Figure 2). The calibration cur ve in Figure 3 shows the average area of the five replicates plotted against the amount injected.

Ritanserin Five replicates at five different concentration levels were run. FIA injections of Ritanserin at its lowest detectable limit, 10 pg/mL (50 fg on-column), is shown in Figure 4. At a concentration 10 times lower than Raclopride, Ritanserin is easily detected. With a S/N ratio of more than 20:1 at 10 pg/mL, it should be possible to achieve even lower limits of detection for Ritanserin.

Conclusion

The ability to accurately detect low levels of analytes is an essential requirement for many pharmaceutical, toxicological, and clinical applications. The data presented in this application note illustrates that the Varian 1200L triple quadrupole mass spectrometer is capable of achieving very reproducible results at femtogram levels for compounds such as Ritanserin and Raclopride.

References

1. http://www.books.md/R/dic/ritanserin.php

2. http://www.online-medical-dictionary.org/?q=Raclopride

3. Forngren, B.H. Liquid Chromatography-Mass Spectrometry in the Analysis of Radiolabelled Compounds for Positron Emission Tomography. Acta Universitaris Upsaliensis. Comprehensive Summaries of Uppsala Dissertations from the Faculty of Science and Technology 586. 56pp. Uppsala. ISBN 91-554-4810-0


'"/>

Source:


Page: All 1 2

Related biology technology :

1. Improved Sensitivity for Staining RNA with SYBR Gold Stain
2. Enhancing Ruggedness and Full-Scan MS Sensitivity Using Ion Sweep Technology
3. Increase the Power and Sensitivity for Your cDNA Synthesis with the New Transcriptor Reverse Transcriptase
4. Increased Sensitivity in Microarray Analysis
5. Maintaining High Sensitivity when Working with Small-Volume Samples
6. High Sensitivity, Wide Dynamic Range, Horseradish Peroxidase (HRP) ELISA Using the LMax Microplate Luminometer (MaxLine Application Note #41)
7. Sensitivity and Quantitation using a Finnigan LCQ Deca XP Plus Ion Trap Mass Spectrometer
8. Increased Analyte Sensitivity through the Utility of Enhanced Mass-Resolution on the FinniganTSQ Quantum Discovery
9. Trace Analysis Optimizing Sensitivity Finnigan Surveyor PDA Detector
10. A Screen of shRNAs Targeting Tumor Suppressor Genes to Identify Factors Involved in Paclitaxel Sensitivity
11. Simultaneous Screening of 23 Drugs of Abuse in Oral Fluid Using an LC/MS/MS Method
Post Your Comments:
*Name:
*Comment:
*Email:


(Date:11/30/2016)...   Merck , a leading science and technology ... set of agreements with Evotec AG, whereby Evotec AG ... reagents such as CRISPR and shRNA libraries. Combining access ... accelerated pathway to explore and identify new drug targets. ... new targets, a process that can be time- and ...
(Date:11/30/2016)... ... November 30, 2016 , ... T3D ... a new orally administered treatment for Alzheimer’s disease (AD), today announced that CEO, ... 2a clinical trial of T3D-959 in mild to moderate Alzheimer’s patients at CTAD ...
(Date:11/30/2016)... ... 30, 2016 , ... ProMIS Neurosciences (“ProMIS” or the “Company”), ... today announced that all five of its validated monoclonal antibody (mAb) therapeutic candidates ... prion-like forms of Amyloid beta (Aß) in vitro. , “We previously demonstrated that ...
(Date:11/30/2016)... FRANCISCO , November 30, 2016 The global  HIV-1 ... 2025, growing at a CAGR of 1.4%. According to a new report by ... public health issues worldwide. Continue Reading ... ... , , ...
Breaking Biology Technology:
(Date:6/7/2016)...  Syngrafii Inc. and San Antonio Credit Union ... integrating Syngrafii,s patented LongPen™ eSignature "Wet" solution into ... result in greater convenience for SACU members and ... existing document workflow and compliance requirements. ... Highlights: ...
(Date:6/2/2016)...   The Weather Company , an IBM Business (NYSE: ... capability in which consumers will be able to interact with ... via voice or text and receive relevant information about the ... Marketers have long sought an advertising solution that can create ... relevant and valuable; and can scale across millions of interactions ...
(Date:5/24/2016)... patient care by providing unparalleled technology to leaders of the medical imaging industry.  As ... added to the range of products distributed by Ampronix. Photo - ... ... ... ...
Breaking Biology News(10 mins):